Immunotech Biopharm Ltd (HK:6978)
:6978
Want to see HK:6978 full AI Analyst Report?
6978 Stock Chart & Stats
HK$2.68
-HK$0.01(-0.43%)
At close: 4:00 PM EST
HK$2.68
-HK$0.01(-0.43%)
Day’s Range― - ―
52-Week RangeHK$0.70 - HK$5.40
Previous CloseN/A
Volume50.00K
Average Volume (3M)1.34M
Market Cap
HK$438.43M
Enterprise ValueHK$731.74M
Total Cash (Recent Filing)HK$154.63M
Total Debt (Recent Filing)HK$440.26M
Price to Earnings (P/E)―
Beta0.59
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.42
Shares Outstanding617,500,800
10 Day Avg. Volume1,608,107
30 Day Avg. Volume1,338,788
Financial Highlights & Ratios
PEG Ratio-0.46
Price to Book (P/B)-103.70
Price to Sales (P/S)0.00
P/FCF Ratio-12.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt ReductionA material drop in total debt materially reduces near-term interest and refinancing pressure and improves the company's headline solvency profile. If sustained, lower nominal debt enhances financial flexibility and lengthens runway, lowering the structural risk of imminent liquidity distress.
Improving Cash Burn TrendA multi-year reduction in free cash burn signals better cost control and operational efficiency. This trend, if continued, meaningfully extends funding runway and reduces the frequency and size of external financings required for a pre-commercial biotech, improving long-term viability.
Narrowing Net LossesProgress toward smaller annual net losses reflects operational adjustments or program prioritization. Persistent narrowing is a durable positive signal: it demonstrates management can slow expense growth vs. past levels, which is essential for moving toward break-even once revenue generation begins.
Bears Say
No Reported RevenueAbsence of any reported revenue over multiple years is a fundamental constraint: the company is pre-commercial and lacks product-derived cash flow. This creates long-term dependence on external funding, increasing dilution risk and making sustainable growth contingent on successful commercialization or partnerships.
Negative EquityNegative shareholders' equity is a structural solvency red flag that limits borrowing capacity and strategic flexibility. It raises creditor and counterparty concerns, can trigger covenant issues, and increases the likelihood that future capital must be raised on dilutive or suboptimal terms.
Persistent Operating Cash BurnConsistent, sizable negative operating cash flow shows the business is not self-funding and remains dependent on external capital. That persistent burn constrains R&D pacing and commercialization investments and elevates the risk of repeated financings that can dilute shareholders and disrupt long-term planning.
Immunotech Biopharm Ltd News
6978 FAQ
What was Immunotech Biopharm Ltd’s price range in the past 12 months?
Immunotech Biopharm Ltd lowest stock price was HK$0.70 and its highest was HK$5.40 in the past 12 months.
What is Immunotech Biopharm Ltd’s market cap?
Immunotech Biopharm Ltd’s market cap is HK$438.43M.
When is Immunotech Biopharm Ltd’s upcoming earnings report date?
Immunotech Biopharm Ltd’s upcoming earnings report date is Aug 21, 2026 which is in 74 days.
How were Immunotech Biopharm Ltd’s earnings last quarter?
Immunotech Biopharm Ltd released its earnings results on Mar 20, 2026. The company reported -HK$0.208 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.208.
Is Immunotech Biopharm Ltd overvalued?
According to Wall Street analysts Immunotech Biopharm Ltd’s price is currently Overvalued.
Does Immunotech Biopharm Ltd pay dividends?
Immunotech Biopharm Ltd does not currently pay dividends.
What is Immunotech Biopharm Ltd’s EPS estimate?
Immunotech Biopharm Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immunotech Biopharm Ltd have?
Immunotech Biopharm Ltd has 617,500,800 shares outstanding.
What happened to Immunotech Biopharm Ltd’s price movement after its last earnings report?
Immunotech Biopharm Ltd reported an EPS of -HK$0.208 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.959%.
Which hedge fund is a major shareholder of Immunotech Biopharm Ltd?
Currently, no hedge funds are holding shares in HK:6978
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immunotech Biopharm Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
62.94%
12-Months-Change
Fundamentals
Return on Equity
293.08%
Trailing 12-Months
Asset Growth
11.88%
Trailing 12-Months
Company Description
Immunotech Biopharm Ltd
Immunotech Biopharm Ltd operates as a biopharmaceutical firm specializing in cellular immunotherapy. Its primary activities involve the investigation, development, and market introduction of T cell-based immunotherapy solutions for various cancers within the People's Republic of China. The company's flagship product, EAL, is a multi-target cellular immunotherapy currently undergoing Phase II clinical trials for the purpose of preventing liver cancer recurrence after surgery. Furthermore, Immunotech Biopharm is conducting both preclinical and clinical research on EAL for its potential use in treating lung cancer, glioma, gastric cancer, and colorectal cancer. Other pipeline assets include the 6B11-OCIK injection, which is in Phase I trials for ovarian cancer; the CAR-T-19 injection product, targeting B-cell acute lymphoblastic leukaemia; and a range of TCR-T cell products designed for solid tumor treatment. Established in 2006, the company's main office is located in Beijing, China.
Technical Analysis
TOT BIOPHARM International Co. Ltd.
―
Jiangsu Recbio Technology Co., Ltd. Class H
―
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
―
SinoMab Bioscience Ltd.
―
Zhaoke Ophthalmology Ltd.
―
Options Prices
Currently, No data available
---